摘要
目的观察丹酚酸B对原发性高血压大鼠(SHR)的降压作用,并探讨其可能的降压机制。方法将64只雄性SHR大鼠随机分为4组:模型组,阳性药组(依那普利组),丹酚酸B(SalB)高、低剂量组,另设正常对照组(16只健康大鼠),分别给予相应药物或蒸馏水。给药前分别测基础血压1次,给药后每2周测血压1次,给药10周后取一半大鼠检测各组大鼠血压,血浆肾素(PRA)、血管紧张素I(IAng-Ⅱ)、内皮素(ET)、心钠素(ANF)含量,血清一氧化氮(NO)、胆固醇(TC)、甘油三酯(TG)、超氧化物歧化酶(SOD)及丙二醛(MDA)含量。其余大鼠停药2周后再测上述指标。结果与正常对照组比较,模型组大鼠血压、TG、NO、PRA、Ang-Ⅱ及MDA含量均明显升高(P<0.01);与模型组比较,丹酚酸B有明显降血压作用(P<0.01),丹酚酸B能够降低SHR的PRA、Ang-Ⅱ含量,升高ANF含量(P<0.05),能够降低血清TG含量(P<0.05),对血清ET、NO及TC含量无明显影响(P>0.05),能够降低血清MDA含量(P<0.05),但对血清SOD含量无明显影响(P>0.05)。结论丹酚酸B对SHR具有一定的降压作用,其机制可能与调节肾素-血管紧张素-醛固酮系统(RAAS)、血清ANF、TG水平及抗氧化作用有关。
Objective To investigate the hypotensive effects of salvianolic acid B(Sal-B)on spontaneous hypertensive rats(SHRs).Methods Sixty-four male SHRs were randomly divided into four groups,SHR group,enalapril group,high-dose Sal-B group and low-dose Sal-B group.Sixteen male WKY rats were selected as normal blood pressure control group.Systolic blood pressure was measured before medication and every two weeks after drug administration.After ten weeks of drug administration,half of the mice in each group were given the examination of blood pressure,plasma renin activity,angiotensinⅡ(AngⅡ),endothelin(ET)and atrial natriuretic factor(ANF)contents,and serum nitric oxide(NO),total cholestero(l TC),triglyceride(TG),superoxide dismutase(SOD),and malondialdehyde(MDA)levels.Two weeks after suspension of drug administration,the above indexes were examined in the left half of the mice.Results Blood pressure and plasma levels of TG,NO,renin activity,AngⅡ and MDA in SHR group were significantly higher than those of the normal control group(P 0.01).Sal-B significantly decreased blood pressure(P 0.01),reduced blood renin,AngⅡ,TG and MDA levels(P 0.05),increased ANF levels(P 0.05),which were remarkably different from the SHR group.However,Sal-B had no obvious effect on ET,NO,TC and SOD levels(P 0.05).Conclusion Sal-B can lower blood pressure of SHRs,and the possible mechanism may be related with the regulation of renin-angiotensin-aldosterone system(RAAS),blood ANF and TG levels,and anti-oxidation activity.
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2013年第4期374-379,共6页
Traditional Chinese Drug Research and Clinical Pharmacology